Relay Therapeutics
215 First Street, 3rd Floor
Cambridge
Massachusetts
02142
United States
Tel: 617-370-8837
Website: http://relaytx.com/
About Relay Therapeutics
Relay Therapeutics was founded on the premise that putting protein motion at the heart of drug discovery can dramatically expand therapeutic possibilities.
YEAR FOUNDED:
February 2016
LEADERSHIP:
CSO and Co-Founder: Mark Murcko, Ph.D.
CEO: Sanjiv Patel
VP, Corporate Development and Strategy: Deborah Palestrant
JOBS:
113 articles about Relay Therapeutics
-
Relay Therapeutics to Participate in Three Upcoming Investor Conferences
2/26/2024
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats.
-
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
2/22/2024
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2023 financial results and corporate highlights.
-
Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
2/15/2024
Relay Therapeutics, Inc. will report fourth quarter and full year 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 22, 2024.
-
Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
2/1/2024
Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 10:30 a.m. ET.
-
Relay Therapeutics Announces $30 Million Private Placement Financing
1/8/2024
Relay Therapeutics, Inc. announced that it has entered into a securities purchase agreement for a private placement financing with Nextech to sell an aggregate of 2.5 million shares of common stock at a price per share of $12.00, a premium to the closing price on January 5, 2024, that is expected to result in gross proceeds of $30.0 million.
-
Relay Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 2:15 p.m. PT.
-
Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference
11/7/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that management will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023 at 1:50 p.m. ET.
-
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
11/2/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2023 financial results and corporate highlights.
-
Relay Therapeutics to Announce Third Quarter 2023 Financial Results and Corporate Highlights on November 2, 2023
10/26/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2023 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 2, 2023.
-
The biotech will pause its lirafugratinib program for a rare bile duct cancer to target a larger FGFR2-altered solid tumors population, citing the Inflation Reduction Act as a driving decision factor.
-
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
10/12/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced initial clinical data for RLY-4008 (lirafugratinib) in patients with FGFR2-altered solid tumors.
-
Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9/18/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced that data for RLY-4008 (lirafugratinib) in patients with advanced FGFR2-altered solid tumors outside of cholangiocarcinoma will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023.
-
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
8/8/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported second quarter 2023 financial results and corporate highlights.
-
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
8/1/2023
Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2023 financial results and corporate highlights after the U.S. financial markets close on Tuesday, August 8, 2023.
-
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported results
5/25/2023
Relay Therapeutics, Inc. announced complete first-in-human dose escalation data for RLY-4008, an investigational, potent, selective and oral small molecule inhibitor of fibroblast growth factor receptor 2.
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences - May 24, 2023
5/24/2023
Relay Therapeutics, Inc. announced that management will participate in two upcoming fireside chats.
-
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
5/4/2023
Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, reported first quarter 2023 financial results and corporate highlights.
-
Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
4/27/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report first quarter 2023 financial results and corporate highlights after the close of market on Thursday, May 4, 2023.
-
Relay Therapeutics to Participate in Two Upcoming Investor Conferences - April 19 2023
4/19/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two upcoming fireside chats.
-
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
4/18/2023
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced initial clinical data for RLY-2608, the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα.